Filing Details

Accession Number:
0001104659-15-074205
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-10-29 18:14:31
Reporting Period:
2015-10-27
Filing Date:
2015-10-29
Accepted Time:
2015-10-29 18:14:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1592288 Dimension Therapeutics Inc. DMTX Biological Products, (No Disgnostic Substances) (2836) 463942159
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1537370 Rishi Gupta C/O Dimension Therapeutics, Inc.
840 Memorial Drive, 4Th Floor
Cambridge MA 02139
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-10-27 3,250,085 $0.00 3,250,085 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2015-10-27 1,947,613 $0.00 5,197,698 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2015-10-27 200,000 $13.00 5,397,698 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2015-10-27 9,500,000 $0.00 3,250,085 $0.00
Common Stock Series B Preferred Stock Disposition 2015-10-27 5,692,874 $0.00 1,947,613 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series A Preferred Stock automatically converted into Common Stock, for no additional consideration, on a 2.923-for-1 basis at the closing of the Issuer's initial public offering, and had no expiration date.
  2. The Series B Preferred Stock automatically converted into Common Stock, for no additional consideration, on a 2.923-for-1 basis at the closing of the Issuer's initial public offering, and had no expiration date.
  3. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V. OrbiMed Advisors LLC ("Advisors") is the managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.
  4. Each of GP V, Advisors, Isaly, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.